Data from Pharmawand - Curated by EPG Health - Date added 12 July 2018

Takeda Pharmaceutical announced that the randomized, Phase III TOURMALINE-MM3 study met its primary endpoint, demonstrating single-agent oral Ninlaro (ixazomib) as a maintenance therapy in multiple myeloma resulted in a statistically significant improvement in progression-free survival (PFS) versus placebo. The trial evaluated the effect of Ninlaro as a maintenance therapy in adult patients diagnosed with multiple myeloma who responded to high-dose therapy (HDT) and autologous stem cell transplant (ASCT). There were no new safety signals found in TOURMALINE-MM3. The safety profile of Ninlaro in the maintenance setting is consistent with previously reported results of single-agent Ninlaro use.

Full data results will be submitted for presentation at the 60th American Society of Hematology Annual Meeting in December. Takeda plans to submit data from the trial to regulatory agencies around the world. Ninlaro is currently not approved as a maintenance therapy for multiple myeloma following ASCT.

Comment: Ninlaro was approved by the FDA in November 2015 following a priority review and by the European Commission in November 2016. In the U.S. and Europe, Ninlaro is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.

Comments

You will need to login, to leave a comment.

epgonline.org is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

Biosimilars in Oncology Knowledge Centre

Biosimilars in Oncology Knowledge Centre

What are biologics and how do they differ from small molecule medicines? Discover more about their development, as well as the manufacturing and regulatory processes in the Biosimilars in Oncology Knowledge Centre.

Inflammatory Bowel Disease Knowledge Centre

Inflammatory Bowel Disease Knowledge Centre

The Inflammatory Bowel Disease (IBD) Knowledge Centre contains key information relating to the epidemiology and pathophysiology of Crohn’s disease and ulcerative colitis, highlighting prevalence, impact and unmet needs and the underlying inflammatory processes that drive IBD, considering some of the key inflammatory pathways.

Load more

Related Content